• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Wilson Perrin Megan

    6/23/25 4:15:07 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLYM alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Wilson Perrin Megan

    (Last) (First) (Middle)
    C/O CLIMB BIO, INC.
    20 WILLIAM STREET, SUITE 145

    (Street)
    WELLESLEY HILLS MA 02481

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/17/2025
    3. Issuer Name and Ticker or Trading Symbol
    Climb Bio, Inc. [ CLYM ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Business Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) (1) 02/09/2035 Common Stock 600,000 $1.58 D
    Explanation of Responses:
    1. The option was granted on February 10, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through February 10, 2029, subject to the Reporting Person's continued service.
    Remarks:
    Exhibit Index: 24.1 - Power of Attorney
    /s/ Chandra Adams, as Attorney-in-Fact 06/23/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CLYM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLYM

    DatePrice TargetRatingAnalyst
    6/6/2025$10.00Outperform
    Oppenheimer
    5/22/2025$7.00Buy
    BTIG Research
    12/2/2024$10.00Outperform
    Leerink Partners
    More analyst ratings

    $CLYM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Wilson Perrin Megan

      3 - Climb Bio, Inc. (0001768446) (Issuer)

      6/23/25 4:15:07 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Senior Vice President, Finance Driscoll Cindy

      4 - Climb Bio, Inc. (0001768446) (Issuer)

      6/20/25 4:20:07 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Finance & CAO Pimblett Emily converted options into 5,000 shares and sold $1,540 worth of shares (1,242 units at $1.24), increasing direct ownership by 25% to 18,888 units (SEC Form 4)

      4 - Climb Bio, Inc. (0001768446) (Issuer)

      6/20/25 4:20:04 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLYM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Climb Bio with a new price target

      Oppenheimer initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $10.00

      6/6/25 8:35:04 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Climb Bio with a new price target

      BTIG Research initiated coverage of Climb Bio with a rating of Buy and set a new price target of $7.00

      5/22/25 8:24:05 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Climb Bio with a new price target

      Leerink Partners initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $10.00

      12/2/24 9:55:08 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care